Recent Updates
Recently added Catalysts
MIRA Positive Sentiment

MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction

Tuesday, September 30, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: MIRA Pharmaceuticals has successfully completed the acquisition of SKNY Pharmaceuticals, which enhances its pipeline with the addition of SKNY-1, targeting obesity and nicotine addiction. The acquisition also contributes $5 million in marketable securities, bolstering MIRA's financial stability. This strategic move complements MIRA's ongoing programs, including Ketamir-2 and MIRA-55.
Price reaction · baseline $1.33 (2025-09-29 close) · hit pre-market · clean, no other MIRA news in the window
day 0 close · peak
+2.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Acquisition strengthens MIRA's financial position.
  • Addition of SKNY-1 enhances the product pipeline.
  • The deal adds $5 million in marketable securities.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+5%
120-day peak, hindsight
Typical move
0.6%
average across 2 past catalysts
Cash runway
~21 mo
Low dilution risk

Full Press Release Details

Closing adds $5 million in marketable securities, strengthens financial position, and complements MIRA’s advancing programs including Ketamir-2 and MIRA-55 MIAMI, FLORIDA / ACCESS Newswire / September 30, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company focused on developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced that it has completed its acquisition of SKNY Pharmac…
You can read the full content here

Frequently Asked Questions

What did MIRA Pharmaceuticals acquire?

MIRA Pharmaceuticals acquired SKNY Pharmaceuticals.

How much did MIRA gain in marketable securities?

MIRA gained $5 million in marketable securities from the acquisition.

What is SKNY-1 targeting?

SKNY-1 targets obesity and nicotine addiction.

What are MIRA's ongoing programs?

MIRA's ongoing programs include Ketamir-2 and MIRA-55.

ShareAdd on Google
Tags: MIRA Viatris Investor Conferences Healthcare MIRA Pharmaceuticals SKNY Pharmaceuticals SKNY-1 obesity nicotine addiction
Last updated: Sep 30, 2025

Biotech snapshot

Cash runway
$9M liquidity · $0M/mo burn
~21 mo
Low dilution risk

Catalyst track record

+5%
best trade around MIRA's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for MIRA.

See every catalyst's timing & PoA →